Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

-EU and UK filings completed in 2022; submissions validated by EMA and MHRA and the review procedure has begun as of January 2023-

... | April 3, 2023

Related Keywords

Boston ,Massachusetts ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Australia ,San Francisco ,California ,Switzerland ,London ,City Of ,America ,American ,Phuong Khanh ,Carmen Bozic ,Therapeutics Inc ,American Society Of Hematology ,Facebook ,Drug Administration ,Youtube ,Vertex Pharmaceuticals Incorporated Nasdaq ,Global Medicines Development ,Twitter ,Regulatory Agency ,Linkedin ,Exchange Commission ,European Commission ,European Medicines Agency ,Vertex Pharmaceuticals ,Viacyte Inc ,Instagram ,Vertex Pharmaceuticals Incorporated ,Biologics License Applications ,Priority Review ,American Society ,Annual Meeting ,Executive Vice President ,Medical Affairs ,Chief Medical Officer ,Regenerative Medicine Advanced Therapy ,Fast Track ,Orphan Drug ,Rare Pediatric Disease ,Marketing Authorization Applications ,Orphan Drug Designation ,Priority Medicines ,Innovation Passport ,Innovative Licensing ,Access Pathway ,New England Journal ,Gene Editing Process ,Innovation District ,North America ,Top Employers ,Best Workplaces ,Private Securities Litigation Reform Act ,While Vertex ,Vertex Pharmaceuticals Stock Exchange ,News ,Information ,Press Release ,End ,Uk ,Filings ,Ompleted ,N ,Submissions ,Validated ,Y ,Ma ,Phra ,The ,Review ,Procedure ,Gas ,Egun ,Us ,F ,Anuary Vrtx Us92532f1003 ,